- Home
- MYI vs REPL Comparison
MYI vs REPL Comparison
Compare MYI & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYI
- REPL
- Stock Information
- Founded
- MYI 1992
- REPL 2015
- Country
- MYI United States
- REPL United States
- Employees
- MYI N/A
- REPL N/A
- Industry
- MYI Investment Bankers/Brokers/Service
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- MYI Finance
- REPL Health Care
- Exchange
- MYI Nasdaq
- REPL Nasdaq
- Market Cap
- MYI 745.8M
- REPL 1.1B
- IPO Year
- MYI N/A
- REPL 2018
- Fundamental
- Price
- MYI $10.94
- REPL $11.93
- Analyst Decision
- MYI
- REPL Strong Buy
- Analyst Count
- MYI 0
- REPL 6
- Target Price
- MYI N/A
- REPL $20.00
- AVG Volume (30 Days)
- MYI 256.7K
- REPL 596.0K
- Earning Date
- MYI 01-01-0001
- REPL 02-12-2025
- Dividend Yield
- MYI 4.81%
- REPL N/A
- EPS Growth
- MYI N/A
- REPL N/A
- EPS
- MYI N/A
- REPL N/A
- Revenue
- MYI N/A
- REPL N/A
- Revenue This Year
- MYI N/A
- REPL N/A
- Revenue Next Year
- MYI N/A
- REPL $1,897.99
- P/E Ratio
- MYI N/A
- REPL N/A
- Revenue Growth
- MYI N/A
- REPL N/A
- 52 Week Low
- MYI $9.32
- REPL $4.92
- 52 Week High
- MYI $11.70
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- MYI 38.84
- REPL 44.53
- Support Level
- MYI $11.17
- REPL $10.68
- Resistance Level
- MYI $11.24
- REPL $12.54
- Average True Range (ATR)
- MYI 0.09
- REPL 0.88
- MACD
- MYI -0.02
- REPL -0.19
- Stochastic Oscillator
- MYI 23.61
- REPL 34.75
About MYI Blackrock MuniYield Quality Fund III Inc
BLACKROCK MUNIYIELD QUALITY FUND III, INC. is a investment management company. Its investment objective is to provide shareholders with a high level of current income exempt from U.S. federal income taxes as is consistent with its investment policies and prudent investment management. The company invests in various sectors such as Transportation; Utilities; Health; Education; Tobacco and others.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.